Scholars Central

Research articlePublished 28 Jul 2023

Comparison of Clinical Outcomes between XEN Gel Stent and PreserFlo Microshunt: A Monocentric Experience

Authors: Fabrizio Giansanti, Giuseppe Quaranta, Federica Serino, G Vicini, Fabrizio Franco

Journal of Clinical and Experimental Ophthalmology

Volume 14 · Issue 4 · Pages 1–5

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Purpose: To compare the clinical efficacy and safety outcomes in patients with Primary Open Angle Glaucoma (POAG) who underwent PreserFlo microshunt implantation and XEN-45 gel stent implantation at a single center. Materials and methods: This is a monocentric retrospective study on patients with POAG treated with XEN-45 gel stent implantation or PreserFlo minishunt implantation at our centre in Florence. We included 31 eyes in 24 patients with XEN-45 and 26 eyes treated with twenty-six eyes in 25 patients with PreserFlo microshunt. All patients underwent a complete preoperative assessment, which included Intraocular Pressure (IOP) measurement with Goldmann Applanation Tonometry (GAT). Follow-up lasted for 12 months. Results: We included 31 eyes treated with XEN-45 gel stent and 26 eyes treated with PreserFlo microshunt. The probability of complete success, meant as IOP ≤ 18 mmHg at month 12 without the need for surgically revising the bleb or reoperation, was of 51.6% in group 1 (XEN45) and 65.3% in group 2 (PreserFlo), without statistically significant difference (P=0.294). IOP dropped from 17.84 ± 4.48 to 13.48 ± 2.55 at month 12 in group XEN45, and from 17.27 ± 4.23 to 13.31 ± 1.54 at month 12 in group PreserFlo (P=0.760). The number of IOP-lowering medications dropped from 2.45 ± 1.26 to 0.24 ± 0.66 (month 12) in the XEN45 group and from 2.65 ± 0.89 to 0.24 ± 0.66 (month 12) in the PreserFlo group, without statically significant differences (P=0.642). Needling rate was 35.4% in group 1 and 11.5% in group 2 (P=0.036). Conclusion: In our experience, both XEN45 gel stent and PreserFlo microshunt demonstrated to be effective and safety with similar results in terms of IOP-lowering and surgical success.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical and Experimental Ophthalmology
  • SubjectOphthalmology & Optometry
  • BylineArticles whose byline prints “Fabrizio Giansanti”
  • BylineArticles whose byline prints “Giuseppe Quaranta”
  • BylineArticles whose byline prints “Federica Serino”
  • BylineArticles whose byline prints “G Vicini”
  • BylineArticles whose byline prints “Fabrizio Franco”